Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > July 2, 2024
Daily News
July 2, 2024
- New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
July 2, 2024
- Sato Named MHLW’s Top Pharmacy Officer; Kiyohara to Steer Drug Pricing Reform
July 2, 2024
- MHLW Shuffles Senior Bureaucrats, Ihara Tapped as Vice Health Minister
July 2, 2024
- PMDA Kicks Off Consultations for Pediatric and Rare Disease Drugs
July 2, 2024
- PMDA Opens 1st Overseas Office in Bangkok
July 2, 2024
- Janssen Rebranded as J&J in Japan as Part of Global Move
July 2, 2024
- Medipal/JCR’s MPS IIIB Drug Now in Line to Enter Clinic
July 2, 2024
- MSD to Transfer Belsomra Distribution Rights to Daiichi Sankyo in Japan
July 2, 2024
- MSD Files Keytruda for Malignant Pleural Mesothelioma in Japan
July 2, 2024
- Eisai to Go Solo on Its 1st ADC after BMS Exits Deal
July 2, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…